Table recapitulating the different outcomes
| . | Overall . | TCRαβ/CD19 . | PTCY . | P value . |
|---|---|---|---|---|
| n | 64 | 40 | 24 | |
| PGF | 12 (18.8) | 7 (17.5) | 5 (20.8) | 1.000 |
| Time to neutrophil engraftment, median (IQR), d | 15 (12-17) | 13 (11-15) | 19 (15.5-24.5) | <.0001 |
| Time to platelet engraftment, median (IQR), d | 13 (11-17) | 13 (11-15.75) | 17 (12.5-21.5) | .036 |
| Allograft acute toxicity | 6 (9.4) | 3 (7.5) | 3 (12.5) | .825 |
| Post-allo VOD | 3 (4.7) | 1 (2.5) | 2 (8.3) | .647 |
| Post-allo microangiopathy | 2 (3.1) | 1 (2.5) | 1 (4.2) | 1.000 |
| Pulmonary hemorrhage | 1 (1.6) | 1 (2.5) | 0 (0.0) | 1.000 |
| Patient with post-HSCT infection in the first 3 mo, n (%) | 37 (57.8) | 23 (57.5) | 14 (58.3) | .577 |
| Viral infection events | 26 | 17 | 9 | .603 |
| Bacterial infection events | 9 | 5 | 4 | .797 |
| Fungal infection events | 7 | 3 | 4 | .213 |
| Unknown origin infections events | 4 | 1 | 2 | .286 |
| aGVHD grade 2-4, n (%) | 18 (28.1) | 8 (20.0) | 10 (41.7) | .114 |
| aGVHD grade 3-4, n (%) | 7 (10.9) | 2 (5.0) | 5 (20.8) | .121 |
| cGVHD, n (%) | .710 | |||
| 0 | 56 (87.5) | 35 (87.5) | 21 (87.5) | |
| Unknown | 1 (1.6) | 1 (2.5) | 0 (0.0) | |
| Yes | 7 (10.9) | 4 (10.0) | 3 (12.5) | |
| Death | 12 (18.8) | 9 (22.5) | 3 (12.5) | .508 |
| Cause of death, n (%) | .368 | |||
| GVHD | 2 (16.7) | 1 (11.1) | 1 (33.3) | |
| Infection | 8 (66.7) | 7 (77.8) | 1 (33.3) | |
| Other | 2 (16.7) | 1 (11.1) | 1 (33.3) |
| . | Overall . | TCRαβ/CD19 . | PTCY . | P value . |
|---|---|---|---|---|
| n | 64 | 40 | 24 | |
| PGF | 12 (18.8) | 7 (17.5) | 5 (20.8) | 1.000 |
| Time to neutrophil engraftment, median (IQR), d | 15 (12-17) | 13 (11-15) | 19 (15.5-24.5) | <.0001 |
| Time to platelet engraftment, median (IQR), d | 13 (11-17) | 13 (11-15.75) | 17 (12.5-21.5) | .036 |
| Allograft acute toxicity | 6 (9.4) | 3 (7.5) | 3 (12.5) | .825 |
| Post-allo VOD | 3 (4.7) | 1 (2.5) | 2 (8.3) | .647 |
| Post-allo microangiopathy | 2 (3.1) | 1 (2.5) | 1 (4.2) | 1.000 |
| Pulmonary hemorrhage | 1 (1.6) | 1 (2.5) | 0 (0.0) | 1.000 |
| Patient with post-HSCT infection in the first 3 mo, n (%) | 37 (57.8) | 23 (57.5) | 14 (58.3) | .577 |
| Viral infection events | 26 | 17 | 9 | .603 |
| Bacterial infection events | 9 | 5 | 4 | .797 |
| Fungal infection events | 7 | 3 | 4 | .213 |
| Unknown origin infections events | 4 | 1 | 2 | .286 |
| aGVHD grade 2-4, n (%) | 18 (28.1) | 8 (20.0) | 10 (41.7) | .114 |
| aGVHD grade 3-4, n (%) | 7 (10.9) | 2 (5.0) | 5 (20.8) | .121 |
| cGVHD, n (%) | .710 | |||
| 0 | 56 (87.5) | 35 (87.5) | 21 (87.5) | |
| Unknown | 1 (1.6) | 1 (2.5) | 0 (0.0) | |
| Yes | 7 (10.9) | 4 (10.0) | 3 (12.5) | |
| Death | 12 (18.8) | 9 (22.5) | 3 (12.5) | .508 |
| Cause of death, n (%) | .368 | |||
| GVHD | 2 (16.7) | 1 (11.1) | 1 (33.3) | |
| Infection | 8 (66.7) | 7 (77.8) | 1 (33.3) | |
| Other | 2 (16.7) | 1 (11.1) | 1 (33.3) |
allo, allograft; IQR, interquartile range; VOD, veno-occlusive disease.
Boldfaced values P values are statistically significant (P < .05).